Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route

Fig. 7

TCR-T and Tranilast bivalent-mediated cytotoxicity. a–e Monovalent and bivalent treatments of Tranilast and TCR-Ts against ECA109(NY-ESO-1+/HLA-A*02:01+) ESCC cells. The killing effect of either Tranilast or TCR-T or a combination of both for each selected TCR-T was quantified by LDH release. f–j Monovalent and bivalent treatments of Tranilast and TCR-Ts against OE19(NY-ESO-1+/HLA-A*02:01+) EADC cells. The killing effect of either Tranilast or TCR-T or a combination of both for each selected TCR-T was quantified by LDH released by the cancer cells. m and n monovalent TCR-Ts or Tranilast treatment against ECA109(NY-ESO-1+/HLA-A*02:01+) cells (m) and OE19(NY-ESO-1+/HLA-A*02:01+) cells (n) using native T cells non-functional TCR-T (TCR-T3), and Tranilast as controls. Data are shown as mean ± SD and compared using one-way ANOVA (Brown-Forsythe and Welch tests) with *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us